Ann: Launch of LUMOS2 Study, page-9

The last Corp deck on their site dates back to Nov '22. It states there are readouts for 4/5 trials in 1H '23, 3 for pax and 1 for evt. it is way beyond time that they informed us as to what the status is on these. They need to either run a townhall or get the PI's out talking about the data. They are out of $ again shortly, none of us deserve another huge dilution.

There are 3 paths for pax to an NDA, a combination of dipg accelerated with a PRV while starting a pivotal for brain mets would be transformative, hopefully triggers a buyout from Merck or Pfizer!

Kazia are at Bio Boston this week, let's hope they are courting some suitors with bags of Covid cash.